The field of weight loss peptides has advanced rapidly, with several compounds now backed by large-scale clinical trials demonstrating unprecedented reductions in body weight. Three peptides hold FDA approval for weight management or related indications, while others remain in clinical development or are limited to research settings. This guide ranks the most effective weight loss peptides based on clinical evidence, regulatory status, and practical considerations for 2026.
All peptides discussed here are prescription medications or research compounds. None should be used without medical supervision.
How We Ranked These Peptides
Rankings in this guide are based on four weighted criteria. Clinical efficacy carries the most weight: we prioritize peptides with the largest mean body weight reductions demonstrated in randomized, placebo-controlled trials. Strength of evidence accounts for trial size, phase, and replication; a Phase 3 trial with thousands of participants outranks a Phase 2 trial with hundreds. Regulatory status reflects whether a peptide has earned FDA approval, which requires meeting rigorous standards for safety, efficacy, and manufacturing quality. Finally, safety profile considers adverse event rates, long-term data availability, and contraindications.
Peptides with FDA approval and robust Phase 3 data occupy the top positions. Investigational compounds with promising but incomplete data follow. Research-grade peptides with limited or failed clinical evidence are ranked last.
1. Tirzepatide: Strongest Clinical Weight Loss
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. It received FDA approval as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023. For a direct comparison with the other leading GLP-1 option, see the semaglutide vs tirzepatide guide. Its dual-receptor mechanism distinguishes it from pure GLP-1 agonists: GIP receptor activation enhances fat oxidation and may improve tolerability, while GLP-1 receptor activation suppresses appetite and slows gastric emptying.
The SURMOUNT clinical trial program established tirzepatide as the most effective FDA-approved weight loss medication. In SURMOUNT-1, participants without diabetes receiving the highest dose (15 mg weekly) achieved a mean weight reduction of 22.5% over 72 weeks, with 63% of participants losing at least 20% of their body weight. SURMOUNT-4 demonstrated that continued treatment maintained weight loss, with participants on tirzepatide achieving a total mean reduction of 25.3% over 88 weeks, while those switched to placebo regained approximately two-thirds of lost weight.
The head-to-head SURMOUNT-5 trial, published in 2025, confirmed tirzepatide's superiority over semaglutide: participants on tirzepatide lost 20.2% of body weight compared to 13.7% for semaglutide at 72 weeks. Body composition analysis from SURMOUNT-1 showed that fat mass accounted for approximately 73% of total weight lost, with lean mass accounting for the remainder.
Common side effects are gastrointestinal (nausea, diarrhea, vomiting, and constipation) and are most pronounced during dose escalation. Like all GLP-1 class medications, tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies.
2. Semaglutide: Most Proven and Accessible
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk, approved as Wegovy for chronic weight management and as Ozempic for type 2 diabetes. It is the most extensively studied weight loss peptide, with clinical data spanning multiple populations, formulations, and treatment durations.
The STEP trial program provided the foundational evidence. STEP 1 demonstrated a mean weight loss of 14.9% over 68 weeks in adults with obesity, with 86% of participants achieving at least 5% weight loss. STEP 5 extended follow-up to 104 weeks, showing durable weight loss of 15.2%. STEP 3, which combined semaglutide with intensive behavioral therapy, achieved 16.0% mean weight loss.
In January 2025, Novo Nordisk reported results from the STEP UP trial evaluating a higher 7.2 mg dose of semaglutide. This dose achieved 20.7% mean weight loss over 72 weeks, with one-third of participants losing 25% or more of their body weight, substantially narrowing the gap with tirzepatide.
Semaglutide offers the broadest range of delivery options. The standard injectable dose (2.4 mg weekly) is the most commonly prescribed. An oral formulation (Rybelsus) is available for type 2 diabetes, with oral obesity formulations in development. The SELECT cardiovascular outcomes trial also demonstrated a 20% reduction in major adverse cardiovascular events, making semaglutide the first obesity medication with proven cardiovascular benefit.
Side effects mirror other GLP-1 agonists: nausea, vomiting, diarrhea, and constipation are common during titration and typically diminish with continued use. The same thyroid C-cell tumor boxed warning applies.
3. Retatrutide: Most Promising Emerging Option
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors, developed by Eli Lilly. It is currently in Phase 3 clinical trials and is not yet FDA-approved. See the semaglutide vs retatrutide and tirzepatide vs retatrutide comparisons for a look at how it stacks up against the approved options. The addition of glucagon receptor activation is designed to increase energy expenditure and hepatic fat oxidation beyond what dual agonists achieve.
Phase 2 trial results published in the New England Journal of Medicine in 2023 showed remarkable efficacy: participants on the highest dose (12 mg) achieved a mean weight reduction of 24.2% at 48 weeks, with 83% losing at least 15% of their body weight. At 24 weeks, the 12 mg group had already lost 17.5%.
In December 2025, Eli Lilly reported topline (not yet peer-reviewed) results from TRIUMPH-4, the first completed Phase 3 trial. Participants with obesity and knee osteoarthritis specifically (not a general obesity population) on retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks, the largest mean weight reduction ever reported in a Phase 3 obesity trial. The trial also showed substantial reductions in osteoarthritis pain, with more than 1 in 8 participants becoming completely pain-free.
Seven additional Phase 3 trials in the TRIUMPH program are expected to report results throughout 2026, evaluating retatrutide in type 2 diabetes, obstructive sleep apnea, chronic low back pain, metabolic dysfunction-associated steatotic liver disease, and cardiovascular outcomes. If these trials confirm the Phase 2 and TRIUMPH-4 findings, retatrutide could receive FDA approval and potentially displace tirzepatide as the most effective available weight loss peptide.
Gastrointestinal side effects are dose-dependent and similar to other incretin-based therapies. Discontinuation rates due to adverse events were 12.2% and 18.2% for the 9 mg and 12 mg doses, respectively, in TRIUMPH-4. Some discontinuations were related to perceived excessive weight loss.
4. Liraglutide: Longest Safety Track Record
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, approved as Saxenda for chronic weight management (3.0 mg daily) and as Victoza for type 2 diabetes (1.8 mg daily). It was the first GLP-1 agonist approved specifically for obesity in 2014, giving it the longest real-world safety record in this class. The liraglutide vs semaglutide comparison covers the key differences in efficacy and dosing between these two established options.
The SCALE Obesity and Prediabetes trial enrolled 3,731 adults without diabetes and demonstrated a mean weight loss of approximately 8% over 56 weeks with liraglutide 3.0 mg, compared to 2.6% with placebo. Approximately 63% of participants lost at least 5% of body weight. In the SCALE Diabetes trial, patients with type 2 diabetes lost 6.0% of body weight.
While these results are modest compared to tirzepatide and semaglutide, liraglutide offers distinct advantages. Its daily injection schedule allows finer dose titration and faster washout if side effects arise. The SCALE Obesity and Prediabetes extension study demonstrated a 79% reduction in the risk of developing type 2 diabetes in prediabetic participants, with the estimated time to diabetes onset 2.7 times longer than placebo.
Liraglutide's side effect profile is consistent with other GLP-1 agonists. The daily dosing schedule can be a drawback for adherence compared to weekly injections, but some patients and prescribers prefer the greater control it provides.
5. Tesamorelin: Best for Visceral Fat Specifically
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog developed by Theratechnologies, approved as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Unlike the GLP-1 class, tesamorelin works by stimulating the pituitary gland to release growth hormone, which in turn promotes lipolysis, particularly in visceral adipose tissue.
Clinical trials demonstrated that tesamorelin reduces visceral adipose tissue (VAT) by approximately 15% after 26 weeks, increasing to 18% at 52 weeks. In a pivotal randomized trial, 69% of tesamorelin-treated patients achieved an 8% or greater reduction in VAT, compared to 33% on placebo. Notably, a landmark study showed tesamorelin reduced hepatic fat by an average of 37% in individuals with HIV-associated nonalcoholic fatty liver disease. Subcutaneous fat remained largely unchanged, demonstrating highly selective visceral fat reduction.
Tesamorelin also improved metabolic markers including triglycerides, non-HDL cholesterol, and adiponectin levels. More recent analyses have shown concurrent increases in skeletal muscle area and density among responders.
The key limitation is its approved indication: tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Off-label use for general weight loss is not well-supported by evidence, and it does not produce the magnitude of total body weight reduction seen with GLP-1 agonists. It is best suited for individuals whose primary concern is visceral abdominal fat accumulation.
6. AOD-9604: Research-Grade Fat Loss Alternative
AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177 to 191 of human growth hormone, modified with a tyrosine residue. It was designed to replicate the lipolytic (fat-burning) properties of growth hormone without its anabolic or diabetogenic effects. The AOD-9604 vs semaglutide comparison puts the evidence for each approach side by side.
Early clinical trials showed modest results. A Phase IIa 12-week randomized trial found participants receiving AOD-9604 (1 mg daily) lost an average of 2.6 kg compared to 0.8 kg with placebo. However, the subsequent Phase IIb trial (536 subjects, 24 weeks) did not meet its primary endpoint for statistically significant weight loss, and clinical development was terminated in March 2007. The Phase IIa result alone does not tell the full story.
Despite this, AOD-9604 maintains a following in the peptide community, partly due to its favorable safety profile (over 900 participants across six controlled trials showed minimal adverse effects) and its theoretical mechanism of stimulating lipolysis without affecting blood glucose or growth. However, no regulatory authority recognizes AOD-9604 as an approved treatment for obesity or weight loss. It remains designated strictly for research use.
The evidence does not support AOD-9604 as a primary weight loss intervention. For individuals drawn to growth hormone-related pathways, tesamorelin (FDA-approved) or GH secretagogues with better-characterized effects represent more evidence-based alternatives.
GH Secretagogues for Body Recomposition
CJC-1295 and Ipamorelin are growth hormone secretagogues frequently used together in body recomposition protocols. Rather than directly suppressing appetite or targeting fat tissue, they work indirectly by amplifying the body's natural growth hormone release, which supports fat metabolism and lean mass preservation.
CJC-1295 is a GHRH analog that extends the natural growth hormone-releasing signal. A clinical study in healthy adults demonstrated that a single injection produced dose-dependent increases in mean plasma GH concentrations of 2 to 10-fold lasting 6 or more days, and IGF-1 elevations of 1.5 to 3-fold lasting 9 to 11 days.
Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates GH release through ghrelin receptor activation. Unlike other GHRPs, it has minimal effects on cortisol and prolactin, giving it a cleaner side effect profile.
The combination targets two separate pituitary receptor systems simultaneously, producing a synergistic GH pulse that neither compound achieves alone. This elevated GH environment promotes fat oxidation, supports lean tissue maintenance, and may improve recovery from exercise, making the stack more relevant for body recomposition than pure weight loss.
These peptides are not FDA-approved for weight loss or body composition. Clinical data supporting their fat loss effects are limited to small studies and mechanistic inferences from growth hormone physiology. They should not be considered substitutes for GLP-1 agonists when significant weight loss is the primary goal.
FDA-Approved vs Research-Grade: What You Need to Know
The distinction between FDA-approved and research-grade peptides is not merely regulatory; it reflects fundamental differences in the quality and quantity of evidence behind each compound.
FDA-approved peptides (semaglutide, tirzepatide, liraglutide for weight loss; tesamorelin for visceral fat) have completed the full regulatory pipeline. This includes Phase 1, 2, and 3 clinical trials enrolling thousands to tens of thousands of participants, manufacturing under current Good Manufacturing Practice (cGMP) standards, and ongoing post-market safety surveillance. When a physician prescribes Wegovy or Zepbound, the formulation has been verified for identity, purity, potency, and sterility.
Research-grade peptides (AOD-9604, CJC-1295, Ipamorelin) lack this infrastructure. They are sold as research chemicals not intended for human use. Purity can vary significantly between suppliers. There is no standardized dosing guidance based on adequately powered clinical trials. Adverse effects may be underreported because use occurs outside formal medical monitoring. This does not mean these peptides are necessarily dangerous, but the risk profile is fundamentally less characterized.
For anyone prioritizing safety and evidence-based outcomes, FDA-approved options are the clear starting point. Research-grade peptides may be of interest to those who have explored approved options without success, but should only be considered under medical supervision and with full awareness of their limitations.
How to Choose the Right Weight Loss Peptide
Selecting a weight loss peptide depends on the intersection of clinical goals, medical history, access, and risk tolerance.
If maximum weight loss is the primary goal and you are working with a prescribing physician, tirzepatide (Zepbound) offers the strongest clinical results among FDA-approved options. Semaglutide (Wegovy) is a close alternative with more extensive long-term data and availability. The higher 7.2 mg semaglutide dose, if accessible, narrows the efficacy gap considerably.
If you have type 2 diabetes, both tirzepatide (Mounjaro) and semaglutide (Ozempic) are approved for glycemic control with substantial weight loss as a secondary benefit. Liraglutide (Victoza/Saxenda) remains an option with the longest prescribing history.
If visceral fat is the specific concern, tesamorelin targets this depot selectively and is the only peptide with FDA approval for visceral fat reduction, though currently limited to the lipodystrophy indication.
If body recomposition is the goal (losing fat while preserving or gaining lean mass), GH secretagogues like CJC-1295 and Ipamorelin may complement a resistance training program, though their effects are modest compared to GLP-1 agonists and the evidence base is limited.
In all cases, peptide therapy works best as part of a comprehensive approach that includes caloric management, regular physical activity (especially resistance training to preserve lean mass), adequate protein intake, and ongoing medical monitoring. No peptide replaces these fundamentals.
Conclusion
The weight loss peptide landscape in 2026 is defined by a clear hierarchy. Tirzepatide and semaglutide lead with the strongest combination of clinical efficacy and regulatory validation, while retatrutide's Phase 3 data suggests it may soon set a new standard. Liraglutide remains a proven option for those who prefer daily dosing or need the longest safety track record. Tesamorelin occupies a unique niche for visceral fat reduction. Research-grade options like AOD-9604 and GH secretagogues offer limited evidence and should be approached with appropriate caution.
The field continues to evolve rapidly. Seven additional Phase 3 retatrutide trials are expected to report in 2026, and higher-dose semaglutide formulations are expanding the ceiling for GLP-1-based weight loss. Patients and clinicians now have more effective, evidence-based options than at any point in the history of obesity pharmacotherapy.